With just 2 doses in 1 month1
HEPLISAV-B delivered protection for patients with factors that typically affect immune response

IN TRIAL 3: 2 doses of HEPLISAV-B provided statistically significantly higher rates of protective immunity vs 3 doses of Engerix-B®

Peak rates of protective immunity1,16
HEPLISAV-B Engerix-B
Total trial population (N=6665) 95.4% 81.3%
Patients with diabetes (N=961) 90.0% 65.1%
Aged 40-70 (N=5434) 94.6% 78.7%
Male (N=3353) 94.5% 78.8%
Obesity (N=3241) 94.7% 75.4%
Smokers (N=2082) 95.9% 78.6%

Trial 3 study design: A clinical trial that evaluated the noninferiority of the rate of protective immunity at Week 28 induced by HEPLISAV-B (N=4537) to Engerix-B (N=2289) in patients with type 2 diabetes mellitus. A secondary immunogenicity objective was to demonstrate the noninferiority of the rate of protective immunity with HEPLISAV-B at Week 24 compared with Engerix-B at Week 28 in all subjects and in subgroups defined by age, sex, body mass index (BMI), and smoking status among adults aged 18 to 70 years.1,16

2011 CDC guidelines recommend adults with diabetes (aged 19-59 years) be vaccinated against hepatitis B7

With just 2 doses in 1 month1
HEPLISAV-B protected more than 90% of patients in the groups studied

IN TRIAL 3: HEPLISAV-B provided statistically significantly higher rates of protective immunity vs Engerix-B—90% and above in the patient populations studied1,16

IN TRIAL 3: HEPLISAV-B provided statistically significantly higher rates of protective immunity vs Engerix-B—90% and above in the patient populations studied IN TRIAL 3: HEPLISAV-B provided statistically significantly higher rates of protective immunity vs Engerix-B—90% and above in the patient populations studied

No results under 90%: consistently higher rates of protection across the patient populations studied16

Engerix-B is a registered trademark of the GSK group of companies.



Study Results — Subpopulations (Trial 3)
HEPLISAV-B Hepatitis B Vaccine (Recombinant), Adjuvantedâ„¢ HEPLISAV-B Hepatitis B Vaccine (Recombinant), Adjuvantedâ„¢

Call 1-84-HEPLISAV (1-844-375-4728)
8 AM to 8 PM, ET, Monday through Friday